A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma
Clinical trial NCT02385669 · TERMINATED
Trial details
- NCT number
- NCT02385669
- Sponsor
- Craig L Slingluff, Jr
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-04-01
- Primary completion
- 2019-09-18
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.